




REUTERS/Dado Ruvic/Illustration/File Photo

THE BIG PICTURE

COVID-19: The race for a vaccine and cure



SPECIAL REPORT: Countries, companies risk billions in race for coronavirus vaccine >>



INSIGHT: How one Indian company could be world's door to a COVID-19 vaccine >>



INSIGHT: Vaccine makers face biggest medical manufacturing challenge in history >>



SPECIAL REPORT: As world approaches 10 million coronavirus cases, doctors see hope in new treatments >>



ANALYSIS: 'At war time speed', China leads COVID-19 vaccine race >>




EXCLUSIVE: EU eyes COVID-19 vaccines at less than \$40, shuns WHO-led alliance >>

Reuters is leveraging its global expertise in health and the pharmaceutical industry – and its deep sourcing with governments and health authorities worldwide – to bring readers and clients an unparalleled view of the fight against COVID-19. Scientists, governments and drugmakers have mounted a historic race to understand the new coronavirus and identify vaccines and treatments that will save lives worldwide. Reuters has been there at every turn, telling the inside story of that campaign and providing exclusive reporting on the advances and setbacks along the way.

WATCH
REUTERS
NEWSMAKER
Scientist, businessman and philanthropist **Dr. William Haseltine** discusses COVID-19

THE BIG PICTURE



REUTERS/Aikis Konstantinidis

UNPARALLELED INSIGHT

- COVID **opens new doors** for China's gene giant
- **'Vaccine nationalism'**: Is it every country for itself?
- The U.S. has more COVID-19 testing than most. So why is it **falling so short**?
- Why COVID-19 is **killing U.S. diabetes patients** at alarming rates
- Bolsonaro bets **'miraculous cure'** for COVID-19 can save Brazil - and his life
- Scientists **hunt pandemic hotspots** in race to test vaccines
- FDA's **lax rules** on coronavirus blood tests open U.S. market to dubious vendors
- As virus advances, doctors **rethink rush** to ventilate
- How Korea **trounced U.S.** in race to test people for coronavirus

EXCLUSIVE NEWS


- EU talks with Pfizer, Sanofi, J&J on COVID vaccines **hit snags**
- U.S. plans **massive** coronavirus vaccine testing effort to meet year-end deadline
- A quarter of Americans **are hesitant** about a coronavirus vaccine
- Novavax execs could get **big payday** even if vaccine fails
- Fauci **bullish on prospects** for U.S. vaccine, not worried about China winning race
- Moderna **spars with U.S. scientists** over COVID-19 vaccine trials
- J&J says **in talks** with Japan, Gates Foundation to lock in deals on COVID-19 vaccine
- Russia, despite theft allegations, **hails deal** to make UK-developed COVID-19 vaccine
- **Vaccine alliance** finds manufacturing capacity for 4 billion doses of coronavirus vaccines
- EU in **advanced talks** with Johnson & Johnson on COVID-19 vaccine deal
- Lilly COVID-19 treatment could be authorized for use **as soon as September**
- Europe to **accelerate trials** of gene-engineered COVID-19 vaccines
- Lonza sets **new goal** to make Moderna COVID-19 vaccine ingredients
- European Investment Bank to **raise COVID-19 fund** to 2 billion euros
- Fearing shortages, EU may deploy **emergency funds** in COVID-19 vaccine race
- Pressed by Trump, U.S. **pushed unproven coronavirus treatment** guidance



JOIN THE GLOBAL MARKETS FORUM ON REFINITIV MESSENGER

An exclusive editorial community for financial market professionals offering additional news and insight on COVID-19 and more.

THE BIG PICTURE



EXPLORE

THE LIFELINE PIPELINE

Treatments and vaccines in development

EYE ON THE STORY

- Long way to go, but WHO **welcomes** vaccine news
- Pharma execs **forecast** aggressive vaccine timeline
- COVID-19 vaccine's **human trials** show promise
- **Africa's first** coronavirus vaccine trial begins
- Coronavirus vaccine possible in **early 2021**
- China would make a coronavirus vaccine a **"global public product"**
- Pfizer, BioNTech get **vaccine 'fast track'** from FDA

TRUSTED VIEWS

Reuters Breakingviews offers unmatched, agenda-setting commentary. Highlights include:

- Coronavirus **vaccine hopes** inflate bubble
- **Corona Capital**: Flying high
- Gilead gives glimpse into **feverish drug market**
- Moderna puts **stock sale opportunism** to test
- Vaccine victory would be **half cure** for economy

HOW TO ACCESS

- In **Eikon**, search COVID and NEWS1 in the News Monitor.
- Explore the economic impact of the coronavirus pandemic using the **COVID-19 Macro Vitals Eikon app**. Search MACROV in Eikon.
- Access the latest stories online at **reuters.com**.
- Get agenda-setting commentary from **Reuters Breakingviews**.
- View **COVID Science**, a regularly-updated curated collection of scientific findings.
- Publishers can access multimedia content from **Reuters Connect**.
- Access market-leading events, reports and expert-driven content for the pharma sector, and more, from **Reuters Events**.
- Check out the **#AskReuters Twitter chat series** on coronavirus.
- Follow Reuters on **Twitter** and **Facebook**.

FOLLOW ALONG WITH REUTERS

Unlock more unrivaled coverage from Reuters and discover the latest editions of Reuters: The Big Picture.